Trademark: 90370290
Status Date
Friday, November 17, 2023
Filing Date
Wednesday, December 9, 2020
Published for Opposition
Tuesday, September 27, 2022
40 custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapeies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
5 pharmaceutical products for the treatment and prevention of cancer and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
42 Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others
Nov 21, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 17, 2023
Sou Extension 2 Granted
Nov 17, 2023
Sou Extension 2 Filed
Nov 17, 2023
Sou Teas Extension Received
May 11, 2023
Notice Of Approval Of Extension Request E-Mailed
May 9, 2023
Sou Extension 1 Granted
May 9, 2023
Sou Extension 1 Filed
May 9, 2023
Sou Teas Extension Received
Nov 22, 2022
Noa E-Mailed - Sou Required From Applicant
Sep 27, 2022
Official Gazette Publication Confirmation E-Mailed
Sep 27, 2022
Published For Opposition
Sep 7, 2022
Notification Of Notice Of Publication E-Mailed
Aug 18, 2022
Approved For Pub - Principal Register
Aug 18, 2022
Teas/Email Correspondence Entered
Aug 17, 2022
Correspondence Received In Law Office
Aug 17, 2022
Teas Response To Office Action Received
Jul 13, 2022
Teas Change Of Correspondence Received
Jul 13, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jul 13, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 22, 2022
Notification Of Non-Final Action E-Mailed
May 22, 2022
Non-Final Action E-Mailed
May 22, 2022
Non-Final Action Written
Apr 6, 2022
Previous Allowance Count Withdrawn
Mar 8, 2022
Withdrawn From Pub - Og Review Query
Feb 19, 2022
Approved For Pub - Principal Register
Feb 18, 2022
Teas/Email Correspondence Entered
Feb 17, 2022
Correspondence Received In Law Office
Feb 17, 2022
Teas Response To Office Action Received
Aug 18, 2021
Notification Of Non-Final Action E-Mailed
Aug 18, 2021
Non-Final Action E-Mailed
Aug 18, 2021
Non-Final Action Written
May 28, 2021
Assigned To Examiner
Feb 16, 2021
New Application Office Supplied Data Entered
Dec 12, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
